
Americold Says Tariff Impact Limited, Offers Cautious Outlook
Atlanta-based cold storage warehouse and logistics operator Americold Realty Trust told Wall Street analysts on May 8 that tariffs and U.S. trade policy have had a limited 'direct' impact on its fast-growing global operations, but are indirectly affecting its future growth.
Americold CEO George Chappelle said during the company's first-quarter conference call that the Atlanta-based cold storage real estate investment trust (REIT) was updating its yearly guidance based on declining consumer confidence related to tariffs, rather than the Trump administration's trade policy itself.
'The prevailing view is that customers have cut their inventories as much as they probably could cut them,' Chappelle said. 'Beyond the direct impacts and the ongoing trade rhetoric, the changing tariff situation has already had an impact on consumer confidence, causing our customers to adjust their product portfolios and driving inventory levels down.'
On a positive note, Chappelle said export and import activity represented only a small percentage of the company's revenues. In addition, owing to the U.S.–Mexico–Canada (USMCA) agreement signed by the Trump administration in 2020 to replace the North American Free Trade Agreement (NAFTA), the nation's largest cold storage operator is exempt from the recent national emergency tariffs.
In addition, although produce and seafood are the largest imported food categories into the United States, they represent only a small percentage of the company's cold storage business.
'In general, our products tend to be center of the plate, relying heavily on proteins, potatoes and prepared foods,' said Chappelle. 'These products historically have been more insulated from demand fluctuations than more expensive, higher-end steak and seafood products.'
Related Stories
5/8/2025
5/8/2025
Based on those changing economic conditions, Americold revised its yearly outlook from $1.51 to $1.59 per adjusted funds from operations (FFO), representing a 4.4 percent decrease to the range of $1.42 to $1.52 per share. Adjusted FFO is a closely watched financial metric in the REIT industry, as it takes net income and adds back items such as depreciation and amortization.
For the three months ending March 31, the Atlanta-based real estate investment trust reported a net loss of $15.1 million, or 6 cents per share, compared with a net income of $9.8 million, or 3 cents per share, in the same period a year ago. Total revenues fell to $629 million, a 5.4 percent decline compared with the first quarter of 2024.
On an adjusted FFO basis, Americold reported first-quarter earnings of $95.7 million, or 35 cents per share, down 8.8 percent compared to $104.9 million, or 37 cents per share, in the same period last year. Wall Street had expected the cold storage operator to report first-quarter adjusted FFO earnings of 35 cents per share on revenue of $667.1 million.
During the conference call ahead of the opening bell on May 8, Chappelle highlighted Americold's
The acquired facility, constructed in 2022, has a capacity of 10.7 million cubic feet and is in the Cedar Port Industrial Park in Baytown, Texas. The acquisition includes approximately 16 acres of adjacent land that could be used for future expansion projects. Following a planned expansion and equipment upgrades, the facility will add approximately 35,700 pallet positions to Americold's cold storage warehouse portfolio, according to company officials.
As part of its aggressive U.S. and global growth, Americold said it still plans to bring previously announced expansion projects in Kansas City, Missouri; Allentown, Pennsylvania; and Dubai, United Arab Emirates into its operations in the second quarter. First announced in February 2024, Americold is investing $127 million through a strategic partnership with Canadian Pacific Kansas City (CPKC) to co-locate Americold warehouse facilities on the CPKC network.
That project, which is expected to create nearly 200 new jobs in Missouri, will support CPKC's MMX service, North America's only single-line rail service for refrigerated shippers between U.S. Midwest markets and Mexico, company officials said.
Americold is also building a new $35 million, state-of-the-art cold storage
Construction began in early 2024 and is expected to more than triple the current capacity in the Dubai market to over 70,000 pallet positions. Globally, Americold now operates 239 climate-controlled warehouses with approximately 1.5 billion refrigerated cubic feet of storage.
Americold's shares fell 5.98 percent, or $1.10, to close at $17.31 on the New York Stock Exchange on May 8. Over the past 52 weeks, the stock has
Americold Realty's dividend yield is 4.76 percent. The company paid $0.92 per share in dividends over the past 12 months. REITs, such as Americold, are required to distribute at least 90 percent of their net earnings to shareholders as dividends.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030
The human microbiome-based drugs and diagnostics market is projected to grow from $393.4M in 2025 to $1.2B by 2030, at a CAGR of 25.6%. Key players include Ferring, Nestlé Health Science, and Vedanta Biosciences. The report covers market trends, competitive landscape, and ESG developments. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Human Microbiome-based Drugs and Diagnostics: Global Markets" report has been added to global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030. The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) microbiome-based drugs and diagnostics are novel approaches to tackling difficult-to-treat diseases. The growing understanding of the human microbiome can be leveraged to fill the gaps in conventional treatment options. A wide range of scientific studies have demonstrated the role of microbiomes in the pathogenesis of various diseases. The microbiome field is also witnessing an increased level of investments from the private and public sectors. Future opportunities in the market lie in exploring microbiomes in other body parts, such as lungs, and developing microbiome-based drugs as combination therapies. Leading companies in the market for human microbiome-based drugs and diagnostics include Ferring, Nestle Health Science (Seres Therapeutics), BiomeBank, Genetic Analysis AS and Vedanta Scope 55 data tables and 51 additional tables Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes An analysis of the key patent grants and recently published patents Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook Profiles of the leading companies, including Ferring Pharmaceuticals, Nestle Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc. Companies Featured BiomeBank EnteroBiotix Ltd. Enterome Ferring Genetic Analysis Illumina Inc. Microbiome Insights Microbiotica Nestle Health Science Oxford Nanopore Technologies plc PacBio SFA Therapeutics Inc. Thermo Fisher Scientific Inc. Vedanta Biosciences Inc. Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Market Dynamics Emerging Technologies Analysis by Segment Regional Analysis Conclusion Chapter 2 Market Overview Overview and Market Definition Different Microbiomes in Humans Microbiome, Human Health and Disease Technologies Aiding Microbiome Research Culturing and Cultivation Strategies for the Development of Microbiome Therapeutics Additive Microbiome Therapy Modulatory Microbiome Therapy Analysis of Macroeconomic Factors Geopolitical Factors Inflation and Currency Exchange Fluctuations Porter's Five Forces Analysis Chapter 3 Market Dynamics Takeaways Market Drivers Growing Evidence of Microbiome-disease Correlation Microbiome-based Diagnostics for Disease Prevention and Monitoring Market Restraints Challenges in Clinical Trial Design Lack of Established Regulatory Frameworks High Costs of Microbiome Therapeutics Market Opportunities Direct-to-Consumer Microbiome Testing Drugs and Diagnostics for Lung and Skin Microbiomes Chapter 4 Regulatory Landscape Regulatory Aspects North America Europe Asia-Pacific Chapter 5 Emerging Technologies Takeaways Emerging Technologies Microbial Ecosystem Therapeutics Metatranscriptome Sequencing Genetically Modified Microbiome Therapeutics Combination and Adjuvant Therapies with Microbiome-based Drugs Novel Preclinical Models Chapter 6 Market Segmentation Analysis Segmentation Breakdown Market Analysis by Type Microbiome-based Drugs Market Analysis by Application Infectious Diseases GI Disorders Metabolic Disorders Cancer Other Diseases Market Analysis by End User Hospitals and Clinics Research Institutions Pharmaceutical Companies Geographic Breakdown Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Takeaways Company Share Analysis Competitive Analysis Venture Funding and Investment Landscape Recent Developments Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective Introduction to ESG ESG Risk Ratings Concluding Remarks Chapter 9 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
AMD Acquires Another Company To Expand AI Arsenal
Advanced Micro Devices, Inc (NASDAQ:AMD) on Wednesday announced the acquisition of Brium, a team of compiler and AI software experts with deep expertise in machine learning, AI inference, and performance optimization. The financial terms of the transaction remain undisclosed. Brium brings advanced software capabilities that strengthen AMD's ability to deliver highly optimized AI solutions across the entire stack. Their work in compiler technology, model execution frameworks, and end-to-end AI inference optimization will play a key role in enhancing the efficiency and flexibility of AMD's AI acquisition marks the latest in a series of targeted investments, following AMD's acquisitions of Silo AI, and Mipsology, that boosts its ability to support the open-source software ecosystem and deliver optimized performance on its hardware. Last week, AMD announced the acquisition of Enosemi, a move to accelerate co-packaged optics innovation for AI systems. The financial terms of the deal remain undisclosed. AMD held $6.06 billion in cash and equivalents as of March 29, 2025. AMD stock plunged 29% in the last 12 months as it grappled with intensifying rivalry from Nvidia Corp (NASDAQ:NVDA), a cooling tech rally, and the Trump administration's tariff policies. AMD reported first-quarter revenue of $7.44 billion, up 36%, beating analyst estimates of $7.13 billion. The chipmaker reported first-quarter adjusted earnings of 96 cents per share, beating analyst estimates of 94 cents per share. AMD expects second-quarter revenue of approximately $7.4 billion, plus or minus $300 million. Analysts are currently forecasting second-quarter revenue of $7.24 billion. Price Action: AMD stock is trading higher by 0.42% to $119.08 premarket at last check Thursday. Read Next:Photo by jamesonwu1972 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ADVANCED MICRO DEVICES (AMD): Free Stock Analysis Report This article AMD Acquires Another Company To Expand AI Arsenal originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Citigroup to axe around 3,500 tech roles in China
Citigroup is trimming its workforce size by approximately 3,500 at two of its technology centres in China, reported Reuters. The aim is to consolidate and streamline the bank's global technology operations to enhance its risk and data management systems. The staffing reductions will affect the China Citi Solution Centres in Shanghai and Dalian, with the bank planning to complete the process by the start of the fourth quarter of this year, the news agency said citing a statement by Citi. The jobs being cut are predominantly full-time positions, a source privy to the development disclosed. Some of the jobs from these centres would be relocated to other technology hubs within the company, although the specifics regarding the number of jobs or their destinations were not provided. This announcement follows last month's report, which indicated that Citigroup was reducing around 200 information technology contractor roles in China. In March, the bank communicated internally its strategy to decrease its reliance on IT contractors and to increase its in-house IT staff, in response to penalties imposed by regulators concerning data governance and control shortcomings. The downsizing in China is part of Citigroup's global restructuring plan, which has also seen the bank scaling back operations in the US, Indonesia, the Philippines, and Poland. The China-based service and technology unit is tasked with delivering financial technology and operations services to support Citigroup's global business operations. Citigroup is currently in the process of establishing a securities unit in China, still maintain the regional presence. Post-reduction, Citigroup's staff count in China is expected to be around 2,000, which includes several hundred employees within the technology division. Citi Japan, Asia North and Australia banking head Marc Luet was quoted by Reuters as saying: "Citi continues to pursue the establishment of a wholly owned securities and futures company in China." "Citigroup to axe around 3,500 tech roles in China " was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.